Untreated Resectable dMMR/MSI-H Colon Cancer
ANABAnaptyBio IncCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Jemperli/Dostarlimab (PD-1 Antagonist) in Untreated Resectable dMMR/MSI-H Colon Cancer. The expected timing is based on the latest available company guidance and may change.
11/04/25:- Pivotal Ph3 AZUR-2 in untreated resectable dMMR/MSI-H colon cancer ongoing; data timing TBA. 03/03/26:- AZUR-2 pivotal Ph3 dMMR/MSI-H colon cancer trial ongoing; topline data expected in 2028. 05/12/26:- AZUR-2 Phase 3 colon cancer trial data expectation reiterated for 2028.
Verification
Confirm timing and program details against the company announcement or filing.